莫沙必利联合黛力新治疗功能性消化不良临床疗效

Mosapride Combined with Dai Lixin on the Treatment of Functional Dyspepsia Clinical Efficacy

目的:观察临床中应用莫沙必利与黛力新联合治疗功能性消化不良的临床疗效。方法:将本院2010年1月-2011年12月收治的120例功能性消化不良患者随机分为对照组与观察组,对照组60例患者给予莫沙必利治疗,而观察组60例患者给予莫沙必利与黛力新联合治疗,观察两组的临床治疗效果。结果:观察组的临床治疗总有效率95.0%高于对照组的78.3%,两组比较差异有统计学意义(P<0.05);观察组不良反应发生率21.7%与对照组的18.3%比较,差异无统计学意义(P>0.05),统计学无意义。结论:临床中对于功能性消化不良采取莫沙必利与黛力新联合治疗具有较好的应用效果,能够提高临床治疗疗效,并且不良反应也较少,值得临床中应用。

Objective：To observe the clinical efficacy of clinical application mosapride combined with Dai Lixin,combination therapy of functional dyspepsia.Method：120 cases of patients with functional dyspepsia in our hospital from January 2010 to December 2011 were randomly divided into control group and observation group,60 patients of the control group were treated with mosapride,while the observation group 60 patients were given mosapride combined with Dai Lixin combination therapy,the clinical outcomes of the two groups were observed.Result：The clinical observation group total effective rate was 95.0%,total effective rate was 78.3%in the clinical treatment of the control group,two sets of data with significant differences （P0.05）,statistically meaningless.Conclusion：Clinical functional dyspepsia to take mosapride combined with Dai Lixin,new combination therapy has a better effect,can improve the clinical efficacy and fewer adverse reactions,worthy of clinical application.